CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade KalVista Pharmaceuticals, Inc. - KALV CFD

11.84
6.89%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.09
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Kalvista Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 11.03
Open* 10.93
1-Year Change* 66.36%
Day's Range* 10.93 - 12.37
52 wk Range 6.26-13.37
Average Volume (10 days) 423.68K
Average Volume (3 months) 6.84M
Market Cap 430.60M
P/E Ratio -100.00K
Shares Outstanding 34.56M
Revenue N/A
EPS -3.06
Dividend (Yield %) N/A
Beta 0.96
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 11.03 -0.15 -1.34% 11.18 11.36 10.95
Mar 26, 2024 11.08 -0.10 -0.89% 11.18 11.25 10.68
Mar 25, 2024 11.10 -0.57 -4.88% 11.67 11.80 11.09
Mar 22, 2024 11.81 -0.17 -1.42% 11.98 12.22 11.70
Mar 21, 2024 12.11 0.04 0.33% 12.07 12.62 12.01
Mar 20, 2024 12.18 0.37 3.13% 11.81 12.20 11.67
Mar 19, 2024 11.79 0.03 0.26% 11.76 12.31 11.56
Mar 18, 2024 11.96 0.30 2.57% 11.66 12.30 11.55
Mar 15, 2024 11.90 -0.34 -2.78% 12.24 12.40 11.84
Mar 14, 2024 12.40 0.31 2.56% 12.09 12.53 12.05
Mar 13, 2024 12.47 0.15 1.22% 12.32 12.72 12.32
Mar 12, 2024 12.46 -0.32 -2.50% 12.78 12.94 12.26
Mar 11, 2024 13.07 -0.90 -6.44% 13.97 14.31 13.03
Mar 8, 2024 14.32 0.47 3.39% 13.85 14.49 13.69
Mar 7, 2024 13.97 0.19 1.38% 13.78 14.03 12.79
Mar 6, 2024 14.35 0.47 3.39% 13.88 14.56 13.88
Mar 5, 2024 13.95 0.18 1.31% 13.77 14.17 13.77
Mar 4, 2024 14.01 -0.10 -0.71% 14.11 14.17 13.77
Mar 1, 2024 14.11 0.47 3.45% 13.64 14.22 13.63
Feb 29, 2024 13.60 0.24 1.80% 13.36 13.76 13.36

KalVista Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Friday, July 5, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2024 Kalvista Pharmaceuticals Inc Earnings Release
Q4 2024 Kalvista Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 0 0 0 12.69 16.127
Revenue 0 0 0 12.69 16.127
Total Operating Expense 110.871 96.613 57.923 53.223 45.947
Selling/General/Admin. Expenses, Total 30.595 26.446 16.637 13.029 10.926
Research & Development 80.276 70.167 41.286 40.194 35.021
Operating Income -110.871 -96.613 -57.923 -40.533 -29.82
Interest Income (Expense), Net Non-Operating 2.183 0.153 1.95 1.763 1.498
Other, Net 15.781 14.121 9.729 9.53 7.63
Net Income Before Taxes -92.907 -82.339 -46.244 -29.24 -20.692
Net Income After Taxes -92.907 -82.339 -46.244 -29.116 -20.816
Net Income Before Extra. Items -92.907 -82.339 -46.244 -29.116 -20.816
Net Income -92.907 -82.339 -46.244 -29.116 -20.816
Income Available to Common Excl. Extra. Items -92.907 -82.339 -46.244 -29.116 -20.816
Income Available to Common Incl. Extra. Items -92.907 -82.339 -46.244 -29.116 -20.816
Diluted Net Income -92.907 -82.339 -46.244 -29.116 -20.816
Diluted Weighted Average Shares 27.8909 24.4731 19.0944 17.7487 15.0809
Diluted EPS Excluding Extraordinary Items -3.33109 -3.36447 -2.42186 -1.64046 -1.38029
Diluted Normalized EPS -3.33109 -3.36447 -2.42186 -1.64046 -1.38029
Dividends per Share - Common Stock Primary Issue
Apr 2023 Jan 2023 Oct 2022 Jul 2022 Apr 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 31.728 26.945 25.883 26.316 26.811
Selling/General/Admin. Expenses, Total 7.777 6.882 7.806 8.13 7.598
Research & Development 23.951 20.063 18.077 18.186 19.213
Operating Income -31.728 -26.945 -25.883 -26.316 -26.811
Interest Income (Expense), Net Non-Operating 1.135 1.329 0.132 -0.275 -0.74
Other, Net 4.288 4.313 3.494 3.549 3.438
Net Income Before Taxes -26.305 -21.303 -22.257 -23.042 -24.113
Net Income After Taxes -26.305 -21.303 -22.257 -23.042 -24.113
Net Income Before Extra. Items -26.305 -21.303 -22.257 -23.042 -24.113
Net Income -26.305 -21.303 -22.257 -23.042 -24.113
Income Available to Common Excl. Extra. Items -26.305 -21.303 -22.257 -23.042 -24.113
Income Available to Common Incl. Extra. Items -26.305 -21.303 -22.257 -23.042 -24.113
Diluted Net Income -26.305 -21.303 -22.257 -23.042 -24.113
Diluted Weighted Average Shares 34.1323 28.2785 24.595 24.5576 24.543
Diluted EPS Excluding Extraordinary Items -0.77068 -0.75333 -0.90494 -0.93828 -0.98248
Diluted Normalized EPS -0.77068 -0.75333 -0.90494 -0.93828 -0.98248
Dividends per Share - Common Stock Primary Issue 0 0 0
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 172.326 193.647 264.264 88.696 115.546
Cash and Short Term Investments 149.375 166.202 248.929 67.714 100.811
Cash & Equivalents 56.238 30.732 50.592 15.789 32.006
Total Receivables, Net 18.644 14.098 10.418 16.527 11.315
Prepaid Expenses 4.307 13.347 4.917 4.455 3.42
Total Assets 183.202 203.88 272.013 92.529 118.132
Property/Plant/Equipment, Total - Net 10.77 10.04 7.549 3.655 2.413
Total Current Liabilities 15.032 11.576 9.774 7.72 18.052
Accounts Payable 4.817 3.638 1.981 1.677 2.86
Accrued Expenses 10.215 7.938 7.793 6.043 5.593
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 9.545
Total Liabilities 22.177 18.787 14.82 8.777 21.394
Total Long Term Debt 0 0 0 0 0
Total Equity 161.025 185.093 257.193 83.752 96.738
Redeemable Preferred Stock
Common Stock 0.034 0.025 0.024 0.018 0.017
Additional Paid-In Capital 507.133 439.104 426.437 207.208 191.123
Retained Earnings (Accumulated Deficit) -343.082 -250.175 -167.836 -121.592 -92.476
Other Equity, Total -3.06 -3.861 -1.432 -1.882 -1.926
Total Liabilities & Shareholders’ Equity 183.202 203.88 272.013 92.529 118.132
Total Common Shares Outstanding 34.1711 24.5508 24.4225 17.8456 17.2778
Other Long Term Assets, Total 0.106 0.193 0.2 0.178 0.173
Current Port. of LT Debt/Capital Leases 0.054
Capital Lease Obligations 0
Other Liabilities, Total 7.145 7.211 5.046 1.057 3.342
Short Term Investments 93.137 135.47 198.337 51.925 68.805
Property/Plant/Equipment, Total - Gross 13.728 12.459 9.638 5.023 3.309
Accumulated Depreciation, Total -2.958 -2.419 -2.089 -1.368 -0.896
Jul 2023 Apr 2023 Jan 2023 Oct 2022 Jul 2022
Total Current Assets 149.842 172.326 192.133 151.216 170.407
Cash and Short Term Investments 123.257 149.375 171.685 122.273 142.075
Cash & Equivalents 49.409 56.238 85.049 38.585 37.863
Short Term Investments 73.848 93.137 86.636 83.688 104.212
Total Receivables, Net 20.57 18.644 12.681 21.93 19.289
Prepaid Expenses 6.015 4.307 7.767 7.013 9.043
Total Assets 160.332 183.202 203.468 162.838 182.319
Property/Plant/Equipment, Total - Net 10.384 10.77 11.138 11.425 11.694
Other Long Term Assets, Total 0.106 0.106 0.197 0.197 0.218
Total Current Liabilities 14.132 15.032 11.606 11.32 9.733
Accounts Payable 5.06 4.817 1.698 3.384 2.908
Accrued Expenses 9.072 10.215 9.908 7.936 6.825
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 20.997 22.177 19.027 19.025 17.747
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 6.865 7.145 7.421 7.705 8.014
Total Equity 139.335 161.025 184.441 143.813 164.572
Common Stock 0.034 0.034 0.034 0.025 0.025
Additional Paid-In Capital 510.591 507.133 504.725 444.588 441.914
Retained Earnings (Accumulated Deficit) -368.399 -343.082 -316.777 -295.474 -273.217
Other Equity, Total -2.891 -3.06 -3.541 -5.326 -4.15
Total Liabilities & Shareholders’ Equity 160.332 183.202 203.468 162.838 182.319
Total Common Shares Outstanding 34.2666 34.1711 34.1278 24.602 24.5709
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -82.339 -46.244 -29.116 -20.816 -15.805
Cash From Operating Activities -78.134 -30.171 -44.816 -36.365 10.558
Cash From Operating Activities 0.564 0.537 0.512 0.378 0.18
Non-Cash Items 15.963 7.19 4.428 2.863 0.409
Cash Interest Paid
Changes in Working Capital -12.322 8.346 -20.64 -18.79 25.774
Cash From Investing Activities 57.86 -147.654 16.753 -69.422 -1.427
Capital Expenditures -0.931 -0.082 -0.22 -1.081 -1.427
Other Investing Cash Flow Items, Total 58.791 -147.572 16.973 -68.341 0
Cash From Financing Activities 1.581 212.117 11.584 87.943 8.986
Issuance (Retirement) of Stock, Net 1.581 212.117 11.638 88.152 9.137
Foreign Exchange Effects -1.167 0.511 0.262 -1.205 1.988
Net Change in Cash -19.86 34.803 -16.217 -19.049 20.105
Issuance (Retirement) of Debt, Net 0 -0.054 -0.209 -0.151
Jan 2023 Oct 2022 Jul 2022 Apr 2022 Jan 2022
Net income/Starting Line -66.602 -45.299 -23.042 -82.339 -58.226
Cash From Operating Activities -52.625 -43.336 -22.742 -78.134 -51.345
Cash From Operating Activities 0.53 0.331 0.158 0.564 0.408
Non-Cash Items 7.168 5.214 3.498 15.963 11.66
Changes in Working Capital 6.279 -3.582 -3.356 -12.322 -5.187
Cash From Investing Activities 47.625 50.142 30.044 57.86 45.426
Capital Expenditures -1.127 -1.112 -0.92 -0.931 -0.845
Other Investing Cash Flow Items, Total 48.752 51.254 30.964 58.791 46.271
Cash From Financing Activities 58.149 0.336 0.168 1.581 1.443
Issuance (Retirement) of Stock, Net 58.149 0.336 0.168 1.581 1.443
Foreign Exchange Effects 1.168 0.711 -0.339 -1.167 -0.539
Net Change in Cash 54.317 7.853 7.131 -19.86 -5.015
Issuance (Retirement) of Debt, Net 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

KalVista Pharmaceuticals, Inc. Company profile

About Kalvista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The Company is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. It has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.

Financial summary

BRIEF: For the nine months ended 31 January 2022, Kalvista Pharmaceuticals Inc revenues was not reported. Net loss increased 86% to $58.2M. Higher net loss reflects Research and development increase of 73% to $51M (expense), General and administrative increase of 80% to $18.8M (expense), foriegn exchange gain/loss decrease from $715K (income) to $529K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.75 to -$2.38.

Industry: Biopharmaceuticals

55 Cambridge Pkwy Ste 901E
CAMBRIDGE
MASSACHUSETTS 02142-1234
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

XRP/USD

0.64 Price
+3.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,218.08 Price
+1.050% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

70,659.20 Price
+2.540% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,236.90 Price
-0.240% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading